Contagion Live: Targeting Lung Blood Vessel Inflammation in COVID-19 Patients
UC cardiologist discusses use of razuprotafib to lessen blood vessel inflammation
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients. Becker, also a UC Health cardiologist, and Duncan Hite, a professor in the UC College of Medicine, and medical director of critical care at UC Health, are overseeing the trial using razuprotafib at UC. The drug is being used as a part of clinical trial in 20 sites across the nation.
Listen to the Contagion Live interview online.
Learn more about the research involving Dr. Becker and Dr. Hite.
Related Stories
Hoxworth teams up with Cincinnati Reds
March 27, 2026
Reds fans and the Greater Cincinnati community have a chance to hit a home run for local hospital patients this April. Hoxworth Blood Center, University of Cincinnati, is teaming up with the Cincinnati Reds to offer donors an exclusive Reds windbreaker as a thank-you gift for giving blood in April.
Satellites show greater urban methane emissions than known
March 27, 2026
ABC News turned to a University of Cincinnati expert in methane emissions for context about a new study that found urban methane emissions are far higher than previously known.
There is no right to remote work
March 26, 2026
The Cincinnati Enquirer spoke with Anne Lofaso, professor in the UC College of Law, about what the law says about reasonable accommodations for employees and how remote work might be part of the conversation.